BioCentury | May 9, 2013
Targets & Mechanisms

AD vaccine redux

...emulsion. Peter Blackburn, cofounder and president of Mercia, said MAS-1 had previously been used in Aphton...
...G17DT), a cancer vaccine against gastrin-17 that failed in Phase III testing for pancreatic cancer. Aphton's...
...now a part of Symphogen A/S . Mercia acquired rights to MAS-1 as part of Aphton's...
BioCentury | May 31, 2010
Finance

Performance Counts

...Corp. QuatRx Pharmaceuticals Co. ND $16.7 Biology: tissue-specific regulation of steroid hormone effects Igeneon AG Aphton Corp....
BioCentury | Sep 3, 2007
Strategy

Back to School 2007: Innovation & leadership

Over the past two years, Back to School has been exploring the relationship between innovation and the economic returns from drug development and the creation of patient value. These discussions have argued that as pricing...
BioCentury | Mar 12, 2007
Company News

t2cure management update

...GmbH , Frankfurt, Germany Business: Gene/Cell therapy Hired: Manfred Ruediger as CEO, formerly COO of Aphton Corp. WIR...
BioCentury | Mar 9, 2007
Company News

t2cure names Ruediger CEO

...as CEO, a new position at the regenerative medicine company. Previously, he was COO of Aphton...
BioCentury | Aug 7, 2006
Company News

Aphton, Receptor BioLogix deal

...to diphtheria toxin. APHTQ filed for Chapter 11 bankruptcy in May (see BioCentury, May 29). Aphton Corp....
BioCentury | Aug 1, 2006
Company News

Receptor Biologix acquires Aphton's Insegia

Receptor Biologix (San Francisco, Calif.) acquired APHTQ's Insegia (G17DT) cancer vaccine in a Chapter 11 bankruptcy sale. Receptor Biologix said it expects to pay no more than $1 million for the product and related assets....
BioCentury | May 29, 2006
Product Development

Late-stage cancer vaccines

...injection every other week Control: Observation arm for RCC trial; physician's choice for melanoma trial Aphton...
BioCentury | May 29, 2006
Product Development

Cancer vaccines in development

...Aphton (A) IGN101 Murine MAb against EpCAM 17-1A Stage IV colorectal cancer Ph II compl Aphton...
BioCentury | May 29, 2006
Company News

Aphton cancer news

...cancer vaccine is in a Phase II/III trial to treat non-small cell lung cancer (NSCLC). Aphton Corp....
Items per page:
1 - 10 of 152
BioCentury | May 9, 2013
Targets & Mechanisms

AD vaccine redux

...emulsion. Peter Blackburn, cofounder and president of Mercia, said MAS-1 had previously been used in Aphton...
...G17DT), a cancer vaccine against gastrin-17 that failed in Phase III testing for pancreatic cancer. Aphton's...
...now a part of Symphogen A/S . Mercia acquired rights to MAS-1 as part of Aphton's...
BioCentury | May 31, 2010
Finance

Performance Counts

...Corp. QuatRx Pharmaceuticals Co. ND $16.7 Biology: tissue-specific regulation of steroid hormone effects Igeneon AG Aphton Corp....
BioCentury | Sep 3, 2007
Strategy

Back to School 2007: Innovation & leadership

Over the past two years, Back to School has been exploring the relationship between innovation and the economic returns from drug development and the creation of patient value. These discussions have argued that as pricing...
BioCentury | Mar 12, 2007
Company News

t2cure management update

...GmbH , Frankfurt, Germany Business: Gene/Cell therapy Hired: Manfred Ruediger as CEO, formerly COO of Aphton Corp. WIR...
BioCentury | Mar 9, 2007
Company News

t2cure names Ruediger CEO

...as CEO, a new position at the regenerative medicine company. Previously, he was COO of Aphton...
BioCentury | Aug 7, 2006
Company News

Aphton, Receptor BioLogix deal

...to diphtheria toxin. APHTQ filed for Chapter 11 bankruptcy in May (see BioCentury, May 29). Aphton Corp....
BioCentury | Aug 1, 2006
Company News

Receptor Biologix acquires Aphton's Insegia

Receptor Biologix (San Francisco, Calif.) acquired APHTQ's Insegia (G17DT) cancer vaccine in a Chapter 11 bankruptcy sale. Receptor Biologix said it expects to pay no more than $1 million for the product and related assets....
BioCentury | May 29, 2006
Product Development

Late-stage cancer vaccines

...injection every other week Control: Observation arm for RCC trial; physician's choice for melanoma trial Aphton...
BioCentury | May 29, 2006
Product Development

Cancer vaccines in development

...Aphton (A) IGN101 Murine MAb against EpCAM 17-1A Stage IV colorectal cancer Ph II compl Aphton...
BioCentury | May 29, 2006
Company News

Aphton cancer news

...cancer vaccine is in a Phase II/III trial to treat non-small cell lung cancer (NSCLC). Aphton Corp....
Items per page:
1 - 10 of 152